Journal of Clinical Oncology
Articles in this Issue
GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.
18 Background: Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality. While aspirin ha...
Targeting chemoresistance: A phase II study of iadademstat (Iada) with paclitaxel (P) in extrapulmonary neuroendocrine carcinoma (epNEC) and small cell lung cancer (SCLC).
633 Background: epNECs and SCLC are aggressive with poor prognosis where chemoresistance limits treatment benefit. Iada is...
Emerging landscape of CAR T-cell therapy in gastrointestinal malignancies: A systematic review of clinical trials.
322 Background: CAR T-cell therapy has transformed hematologic malignancies, but its role in gastrointestinal (GI) cancers...
Real-world outcomes of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A retrospective study from King Fahad Medical City, Saudi Arabia.
492 Background: Hepatocellular carcinoma (HCC) is a significant health burden in Saudi Arabia, commonly diagnosed at inter...
A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.
TPS857 Background: While the most frequently mutated solid tumor oncogenes, RAS an...
Investigating disparities in hepatocellular carcinoma and their effect on patterns of systemic care: An updated analysis.
489 Background: Hepatocellular carcinoma (HCC) disproportionately affects minorities, particularly Black and Hispanic pati...
Oncologists’ perceptions of evidence and standardization in appendiceal cancer management: A national survey.
820 Background: Appendiceal cancers (AC) are rare, histologically diverse malignancies for which evidence-based treatment...
Efficacy and safety of disitamab vedotin (RC48) in combination with sintilimab and XELOX for perioperative therapy of G/GEJ cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.
382 Background: Locally advanced HER2-positive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (cT3-4a/bN+) has a...
Prognostic impact of ctDNA in patients with colorectal cancer and liver metastases: Associations with progression-free and overall survival.
141 Background: Circulating tumor DNA (ctDNA) has the potential to serve as a biomarker for disease monitoring in metastat...
Early gastric cancer recurrence after endoscopic submucosal dissection.
384 Background: Endoscopic submucosal dissection (ESD) is a minimally invasive treatment method for EGC but it is still di...
Single-cell sequencing to reveal immune features of treatment response to neoadjuvant chemoradiotherapy plus immunotherapy in locally advanced rectal cancer.
229 Background: Neoadjuvant chemoradiotherapy plus immunotherapy (NCRIT) shows promise in treating locally advanced rectal...
Myeloid-stromal IL1RAP as a therapeutic vulnerability in pancreatic cancer: Rationale for a neoadjuvant chemoimmunotherapy clinical trial.
745 Background: Pancreatic ductal adenocarcinoma (PDAC) remains highly resistant to chemo- and immune-therapy due to a tum...
Outcomes of SBRT to liver and portal vein tumor thrombus followed by immunotherapy or lenvatinib in BCLC-C hepatocellular carcinoma: A retrospective cohort study.
508 Background: Advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) poses a major therapeutic c...
Alternating neoadjuvant gemcitabine-nab-paclitaxel (GnP) and nal-irinotecan, 5-fluorouracil and folinic acid (nal-IRI) regimens in resectable (R) and borderline resectable (BR) pancreatic cancer (PC): A pilot study.
706 Background: Alternating chemotherapy regimens in PC offers potential advantages of 1) toxicity mitigation 2) therapeut...
Phase Ib/II study of fruquintinib combined with SOX and toripalimab in advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
369 Background: There is an unmet need to improve the efficacy of first-line treatment in advanced GC/GEJC pts with negati...
Development of a treatment strategy for locally advanced pancreatic cancer using carbon-ion radiotherapy: Chemotherapy alone vs. induction chemotherapy followed by carbon-ion radiotherapy.
725 Background: The standard treatment for unresectable locally advanced pancreatic cancer (LAPC) is chemotherapy or chemo...
Impact of time-of-day administration of neoadjuvant chemoradiotherapy on pathologic complete response in esophageal cancer: A multi-site review over two decades.
346 Background: Recent studies have consistently demonstrated associations between survival and time-of-day administration...
Examining the link between tobacco use and gastric cancer mortality: A U.S. population-based perspective (1999–2023).
324 Background: Gastric cancer (GC) remains a major cause of cancer-related mortality, influenced by diverse risk factors...
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
11 Background: Radical chemoradiotherapy (CRT) is the standard of care in patients (pts) with localized squamous cell carc...
Assessing adjuvant chemotherapy benefit in younger and older molecular residual disease–positive patients with stage II/III colorectal cancer.
216 Background: Identifying patients with colorectal cancer (CRC) who derive benefit from adjuvant chemotherapy (ACT) pres...
Analysis of 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) administration in MATTERHORN: A randomized, phase 3 study of durvalumab (D) plus FLOT in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
343 Background: In MATTERHORN (NCT04592913), D + FLOT significantly improved event-free survival (EFS) vs placebo (P) + FL...
Neoadjuvant chemotherapy in resectable gastric cancer: An international propensity-matched analysis of 23,805 patients from high-volume centers across three continents.
413 Background: The role of neoadjuvant chemotherapy (NAC) in resectable, locally advanced gastric cancer is debated, with...
CLDN18.2 IHC cutoff and efficacy of anti-CLDN18.2 therapy in gastric and gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
441 Background: Assay platforms and immunohistochemistry (IHC) cutoffs for CLDN18.2 positivity vary across trials of anti-...
Overall survival of immunotherapy versus standard of care in microsatellite stable metastatic colorectal cancer: A propensity score matched analysis of 708 patients.
202 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite stable (MSS) metastatic colore...
A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( <sup>225</sup> Ac), in patients with neuroendocrine tumors (NETs) and other solid tumors expressing somatostatin receptors (SSTRs).
TPS646 Background: SSTR-targeted RPT has transformed the treatment landscape for NETs, significantly improving clinical ou...